Provascular strategy: Targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment

Radiotherapy and Oncology

Volumn 86, Issue 3, 2008, Pages 300-313

  Sonveaux, Pierre ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Chemotherapy; Combination therapy; Endothelin; Nitric oxide; Radiotherapy; Vasodilation

Indexed keywords

AMBRISENTAN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BOSENTAN; BRADYKININ; CALCIUM ANTAGONIST; CARBOPLATIN; CYCLOPHOSPHAMIDE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FLUNARIZINE; HYDRALAZINE; LEITARIS; LOBRADIMIL; NICOTINAMIDE; NISOLDIPINE; NITRIC OXIDE; RADIOSENSITIZING AGENT; SORAFENIB; UNCLASSIFIED DRUG; VERAPAMIL;

ADAPTATION; ANGIOGENESIS; BIOENERGY; BLOOD FLOW; BLOOD OXYGENATION; BLOOD PH; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CHEMOSENSITIZATION; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; HYPOXIA; LOW DRUG DOSE; LUNG CARCINOMA; MICROENVIRONMENT; NONHUMAN; NUTRIENT SUPPLY; OXYGEN SUPPLY; OXYGEN TENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIOSENSITIVITY; REVIEW; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; VASODILATATION;

EID: 40249089741     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.01.024     Document Type: Review

References (150)

1. M.A. Peinado S. Malkhosyan A. Velazquez M. Perucho Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction Proc Natl Acad Sci USA 89 1992 10065 10069
2. A.V. Gudkov E.A. Komarova The role of p53 in determining sensitivity to radiotherapy Nat Rev Cancer 3 2003 117 129
3. L.H. Gray A.D. Conger M. Ebert S. Hornsey O.C. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 1953 638 648
4. D. Hanahan R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
5. P. Carmeliet R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
6. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat Med 6 2000 389 395
7. R.K. Jain Molecular regulation of vessel maturation Nat Med 9 2003 685 693
8. G. Bergers L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410
9. J. Folkman Tumor angiogenesis R.C. Bast D.W. Kufe R.E. Pollock R.R. Weichselbaum J.F. Holland E. Frei Cancer medicine 5th ed. 2000 BC Decker Inc. Hamilton, Canada
10. R. Kalluri Basement membranes: structure, assembly and role in tumour angiogenesis Nat Rev Cancer 3 2003 422 433
11. H.F. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1986 1650 1659
12. R.K. Jain Determinants of tumor blood flow: a review Cancer Res 48 1988 2641 2658
13. A. Eberhard S. Kahlert V. Goede B. Hemmerlein K.H. Plate H.G. Augustin Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res 60 2000 1388 1393
14. A.S. Lubbe W. Huhnt Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin Int J Microcirc Clin Exp 14 1994 218 225
15. W. Huhnt A.S. Lubbe Venules and arterioles in xenotransplanted human colon adenocarcinoma critically constrict with hyperthermia and serotonin J Cancer Res Clin Oncol 121 1995 267 274
16. O. Thews D.K. Kelleher P.W. Vaupel Modulation of spatial O2 tension distribution in experimental tumors by increasing arterial O2 supply Acta Oncol 34 1995 291 295
17. D. Fukumura F. Yuan M. Endo R.K. Jain Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte–endothelial interactions Am J Pathol 150 1997 713 725
18. D.F. Emerich P. Snodgrass R.L. Dean Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy J Pharmacol Exp Ther 296 2001 623 631
19. C. Julien J.F. Payen I. Tropres Assessment of vascular reactivity in rat brain glioma by measuring regional blood volume during graded hypoxic hypoxia Br J Cancer 91 2004 374 380
20. S. Kashiwagi Y. Izumi T. Gohongi NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels J Clin Invest 115 2005 1816 1827
21. C. Baudelet G.O. Cron R. Ansiaux The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2∗-weighted GRE signal within tumors NMR Biomed 19 2006 69 76
22. J. Mattson L. Appelgren L. Karlsson H.I. Peterson Influence of vasoactive drugs and ischaemia on intra-tumour blood flow distribution Eur J Cancer 14 1978 761 764
23. H.I. Peterson J. Mattson Vasoactive drugs and tumor blood flow Biorheology 21 1984 503 508
24. M.W. Dewhirst H. Kimura S.W. Rehmus Microvascular studies on the origins of perfusion-limited hypoxia Br J Cancer Suppl 27 1996 S247 S251
25. G. Helmlinger F. Yuan M. Dellian R.K. Jain Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation Nat Med 3 1997 177 182
26. T.W. Secomb R. Hsu E.T. Ong J.F. Gross M.W. Dewhirst Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors Acta Oncol 34 1995 313 316
27. C.M. West R.A. Cooper J.A. Loncaster D.P. Wilks M. Bromley Tumor vascularity: a histological measure of angiogenesis and hypoxia Cancer Res 61 2001 2907 2910
28. R.K. Jain L.T. Baxter Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure Cancer Res 48 1988 7022 7032
29. Y. Boucher L.T. Baxter R.K. Jain Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy Cancer Res 50 1990 4478 4484
30. P.A. Netti L.M. Hamberg J.W. Babich Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules Proc Natl Acad Sci USA 96 1999 3137 3142
31. C. Brekken M.H. Hjelstuen O.S. Bruland D.C. de Lange Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts Anticancer Res 20 2000 3513 3519
32. C. Bouzin O. Feron Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery Drug Resist Updat 10 2007 109 120
33. M.J. Boyer I.F. Tannock Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions Cancer Res 52 1992 4441 4447
34. R.A. Gatenby E.T. Gawlinski The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models Cancer Res 63 2003 3847 3854
35. A.G. Ide N.H. Baker S.L. Warren Vascularization of the Brown–Pearce rabbit epithelioma transplant as seen in the transparent ear chamber Am J Roentgenol 42 1939 891 899
36. G.H. Algire H.W. Chalkely F.Y. Legallais H. Park Vascular reactions of normal and malignant tumors in vivo: I. Vascular reactions of mice to wounds and to normal and neoplastic transplants J Natl Cancer Inst 6 1945 73 85
37. G.H. Algire F.Y. Legallais Growth rate of transplanted tumors in relation to latent period and host vascular reaction Cancer Res 7 1947 724
38. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
39. D.J. Good P.J. Polverini F. Rastinejad A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin Proc Natl Acad Sci USA 87 1990 6624 6628
40. M.S. O’Reilly L. Holmgren Y. Shing Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
41. M.S. O’Reilly T. Boehm Y. Shing Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285
42. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803
43. R.C. Kane A.T. Farrell H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278
44. V.L. Goodman E.P. Rock R. Dagher Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 2007 1367 1373
45. D. Mannavola P. Coco G. Vannucchi A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake J Clin Endocrinol Metab 2007
46. C.A. Grandinetti B.R. Goldspiel Sorafenib and sunitinib: novel targeted therapies for renal cell cancer Pharmacotherapy 27 2007 1125 1144
47. F. Lordick H. Geinitz J. Theisen A. Sendler M. Sarbia Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 2006 1295 1298
48. M.S. Ewer J.A. O’Shaughnessy Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer Clin Breast Cancer 7 2007 600 607
49. A. Pande J. Lombardo E. Spangenthal M. Javle Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab Anticancer Res 27 2007 3465 3470
50. P. Sonveaux C. Dessy P. Martinive Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment Cancer Res 64 2004 3209 3214
51. A. Regina J. Jodoin P. Khoueir Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy J Neurosci Res 75 2004 291 299
52. C.W. Song Modification of blood flow M. Molls P. Vaupel Blood perfusion and microenvironment of human tumors 1998 Springer-Verlag Berlin, Germany 193 208
53. R.A. Zlotecki L.T. Baxter Y. Boucher R.K. Jain Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation Microvasc Res 50 1995 429 443
54. D.M. Dudzinski T. Michel Life history of eNOS: partners and pathways Cardiovasc Res 75 2007 247 260
55. P.J. Wood J.M. Sansom I.J. Stratford Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1 Br J Cancer Suppl 27 1996 S177 S180
56. B.F. Jordan P. Misson R. Demeure C. Baudelet N. Beghein B. Gallez Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI Int J Radiat Oncol Biol Phys 48 2000 565 570
57. B.F. Jordan N. Beghein M. Aubry V. Gregoire B. Gallez Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors Int J Cancer 103 2003 138 141
58. S.Q. Shan G.L. Rosner R.D. Braun J. Hahn C. Pearce M.W. Dewhirst Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma Br J Cancer 76 1997 429 437
59. O. Thews D.K. Kelleher P. Vaupel No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs Int J Oncol 19 2001 1243 1247
60. J.B. Mitchell J.A. Cook M.C. Krishna Radiation sensitisation by nitric oxide releasing agents Br J Cancer Suppl 27 1996 S181 S184
61. J.B. Mitchell D.A. Wink W. DeGraff J. Gamson L.K. Keefer M.C. Krishna Hypoxic mammalian cell radiosensitization by nitric oxide Cancer Res 53 1993 5845 5848
62. B.F. Jordan P. Sonveaux O. Feron Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption Int J Cancer 109 2004 768 773
63. P. Wardman K. Rothkamm L.K. Folkes M. Woodcock P.J. Johnston Radiosensitization by nitric oxide at low radiation doses Radiat Res 167 2007 475 484
64. O. Feron Targeting the tumor vascular compartment to improve conventional cancer therapy Trends Pharmacol Sci 25 2004 536 542
65. P. Sonveaux C. Dessy A. Brouet Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery FASEB J 16 2002 1979 1981
66. J. Tan D.E. Hallahan Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response Cancer Res 63 2003 7663 7667
67. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells J Biol Chem 276 2001 32663 32669
68. P. Sonveaux A. Brouet X. Havaux Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy Cancer Res 63 2003 1012 1019
69. P. Sonveaux F. Frerart C. Bouzin Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature Int J Radiat Oncol Biol Phys 67 2007 1155 1162
70. D.H. Gorski M.A. Beckett N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
71. B.J. Moeller Y. Cao C.Y. Li M.W. Dewhirst Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules Cancer Cell 5 2004 429 441
72. F. Li P. Sonveaux Z.N. Rabbani Regulation of HIF-1alpha stability through S-nitrosylation Mol Cell 26 2007 63 74
73. L. Jia C. Bonaventura J. Bonaventura J.S. Stamler S -Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control Nature 380 1996 221 226
74. P. Sonveaux I.I. Lobysheva O. Feron T.J. McMahon Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery Physiology 22 2007 97 112
75. R. Lee K. Neya T.A. Svizzero G.J. Vlahakes Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions J Appl Physiol 79 1995 236 242
76. L.J. Ignarro G.M. Buga K.S. Wood R.E. Byrns G. Chaudhuri Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide Proc Natl Acad Sci USA 84 1987 9265 9269
77. R.M. Palmer A.G. Ferrige S. Moncada Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor Nature 327 1987 524 526
78. P. Sonveaux A.M. Kaz S.A. Snyder Oxygen regulation of tumor perfusion by S -nitrosohemoglobin reveals a pressor activity of nitric oxide Circ Res 96 2005 1119 1126
79. A.I. Alayash Oxygen therapeutics: can we tame haemoglobin? Nat Rev Drug Discov 3 2004 152 159
80. M.P. Moya A.J. Gow T.J. McMahon S -Nitrosothiol repletion by an inhaled gas regulates pulmonary function Proc Natl Acad Sci USA 98 2001 5792 5797
81. M.P. Moya A.J. Gow R.M. Califf R.N. Goldberg J.S. Stamler Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn Lancet 360 2002 141 143
82. T.J. McMahon G.S. Ahearn M.P. Moya A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S -nitrosohemoglobin in pulmonary hypertension Proc Natl Acad Sci USA 102 2005 14801 14806
83. P. Vaupel L. Harrison Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response Oncologist 9 2004 4 9
84. B.F. Jordan V. Gregoire R.J. Demeure Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption Cancer Res 62 2002 3555 3561
85. B.F. Jordan N. Beghein N. Crokart C. Baudelet V. Gregoire B. Gallez Preclinical safety and antitumor efficacy of insulin combined with irradiation Radiother Oncol 81 2006 112 117
86. B.F. Jordan P. Sonveaux O. Feron V. Gregoire N. Beghein B. Gallez Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses Int J Radiat Oncol Biol Phys 55 2003 1066 1073
87. R. Ansiaux C. Baudelet G.O. Cron Botulinum toxin potentiates cancer radiotherapy and chemotherapy Clin Cancer Res 12 2006 1276 1283
88. P. Sonveaux O. Feron Nitric oxide and tumor biology S. Lamas E. Cadenas Nitric oxide, cell signaling, and gene expression 2005 CRC Press Boca Raton, USA 393 418
89. W.G. Haynes D.J. Webb Contribution of endogenous generation of endothelin-1 to basal vascular tone Lancet 344 1994 852 854
90. J.J. Maguire A.P. Davenport ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro Br J Pharmacol 115 1995 191 197
91. J. Nelson A. Bagnato B. Battistini P. Nisen The endothelin axis: emerging role in cancer Nat Rev Cancer 3 2003 110 116
92. B. Battistini P. Chailler P. D’Orleans-Juste N. Briere P. Sirois Growth regulatory properties of endothelins Peptides 14 1993 385 399
93. S.P. Andrade W.T. Beraldo Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors Int J Exp Pathol 79 1998 425 432
94. K.M. Bell V.E. Prise K.M. Shaffi D.J. Chaplin G.M. Tozer A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: influence of tumour size on angiotensin II response Int J Cancer 67 1996 730 738
95. K.M. Bell V.E. Prise D.J. Chaplin S. Wordsworth G.M. Tozer Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats Int J Cancer 73 1997 283 289
96. A. Rai A. Gulati Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor Cancer Chemother Pharmacol 51 2003 21 28
97. G. Aliev M.A. Smith D. Seyidova Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium J Submicrosc Cytol Pathol 34 2002 37 50
98. P. Martinive J. De Wever C. Bouzin Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery Mol Cancer Ther 5 2006 1620 1627
99. F. Yuan M. Dellian D. Fukumura Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res 55 1995 3752 3756
100. L. Rosano F. Spinella D. Salani Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma Cancer Res 63 2003 2447 2453
101. J.E. Donckier J. Mertens-Strijthagen B. Flamion Role of the endothelin axis in the proliferation of human thyroid cancer cells Clin Endocrinol 2007
102. S.G. Thakkar T.K. Choueiri J.A. Garcia Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics Curr Oncol Rep 8 2006 108 113
103. R. Kefford J.M. Beith G.A. Van Hazel A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma Invest New Drugs 25 2007 247 252
104. D. Young New drug approved for pulmonary arterial hypertension Am J Health Syst Pharm 64 2007 1562
105. M.J. Trotter D.J. Chaplin P.L. Olive Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma Eur J Cancer 27 1991 887 893
106. M. Suzuki K. Hori I. Abe S. Saito H. Sato A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II J Natl Cancer Inst 67 1981 663 669
107. O. Thews D.K. Kelleher P. Vaupel Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation Br J Cancer 83 2000 225 231
108. T. Kato Y. Murakami Y. Saito New modality of radiation therapy under increased tumor oxygen tension with angiotensin II: a pilot study Radiat Med 11 1993 86 90
109. H. Ohigashi O. Ishikawa S. Yokayama Intra-arterial infusion chemotherapy with angiotensin-II for locally advanced and nonresectable pancreatic adenocarcinoma: further evaluation and prognostic implications Ann Surg Oncol 10 2003 927 934
110. T. Ishikawa T. Ushiki H. Kamimura Angiotensin-II administration is useful for the detection of liver metastasis from pancreatic cancer during pharmacoangiographic computed tomography World J Gastroenterol 13 2007 3080 3083
111. K. Ino K. Shibata H. Kajiyama A. Nawa S. Nomura F. Kikkawa Manipulating the angiotensin system – new approaches to the treatment of solid tumours Expert Opin Biol Ther 6 2006 243 255
112. P.J. Wood D.G. Hirst Modification of tumour response by calcium antagonists in the SCVII/St tumour implanted at two different sites Int J Radiat Biol 56 1989 355 367
113. P. Vaupel H. Menke Effects of various calcium antagonists on blood flow and red blood cell flux in malignant tumors Prog Appl Microcirc 14 1989 88 103
114. M.W. Dewhirst E.T. Ong D. Madwed Effects of the calcium channel blocker flunarizine on the hemodynamics and oxygenation of tumor microvasculature Radiat Res 132 1992 61 68
115. B.D. Kavanagh B.E. Coffey D. Needham R.M. Hochmuth M.W. Dewhirst The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment Br J Cancer 67 1993 734 741
116. R.L. Jirtle Chemical modification of tumour blood flow Int J Hyperthermia 4 1988 355 371
117. W.T. Bellamy W.S. Dalton J.M. Kailey Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage Cancer Res 48 1988 6365 6370
118. R.F. Ozols R.E. Cunnion R.W. Klecker Jr Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients J Clin Oncol 5 1987 641 647
119. R. Perez-Tomas Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Curr Med Chem 13 2006 1859 1876
120. M.J. Trotter B.D. Acker D.J. Chaplin Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration Int J Radiat Oncol Biol Phys 17 1989 785 789
121. J. Kalmus P. Okunieff P. Vaupel Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors Cancer Res 50 1990 15 19
122. C.A. Belfi C.R. Paul S. Shan F.Q. Ngo Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI Int J Radiat Oncol Biol Phys 29 1994 473 479
123. T. Hasegawa C.W. Song Effect of hydralazine on the blood flow in tumors and normal tissues in rats Int J Radiat Oncol Biol Phys 20 1991 1001 1007
124. J.C. Bremner I.J. Stratford J. Bowler G.E. Adams Bioreductive drugs and the selective induction of tumour hypoxia Br J Cancer 61 1990 717 721
125. L.H. Patterson S.R. McKeown K. Ruparelia Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent Br J Cancer 82 2000 1984 1990
126. M.R. Horsman K.L. Christensen J. Overgaard Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo Int J Hyperthermia 5 1989 123 136
127. P.K. Quinn M.C. Bibby J.A. Cox S.M. Crawford The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours Br J Cancer 66 1992 323 330
128. M. Guichard F. Lespinasse M. Trotter R. Durand D. Chaplin The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts Radiother Oncol 20 1991 117 123
129. Z.M. Bhujwalla G.M. Tozer S.B. Field R.J. Maxwell J.R. Griffiths The energy metabolism of RIF-1 tumours following hydralazine Radiother Oncol 19 1990 281 291
130. H.B. Stone A.I. Minchinton M. Lemmon D. Menke J.M. Brown Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion Int J Radiat Oncol Biol Phys 22 1992 79 86
131. D.J. Honess N.M. Bleehen Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice Int J Radiat Oncol Biol Phys 22 1992 953 961
132. M.W. Dewhirst D.M. Prescott S. Clegg The use of hydralazine to manipulate tumour temperatures during hyperthermia Int J Hyperthermia 6 1990 971 983
133. N.P. Rowell M.A. Flower V.R. McCready B. Cronin A. Horwich The effects of single dose oral hydralazine on blood flow through human lung tumours Radiother Oncol 18 1990 283 292
134. M.W. Dewhirst Z. Vujaskovic E. Jones D. Thrall Re-setting the biologic rationale for thermal therapy Int J Hyperthermia 21 2005 779 790
135. P. Wust B. Hildebrandt G. Sreenivasa Hyperthermia in combined treatment of cancer Lancet Oncol 3 2002 487 497
136. C.W. Song A. Shakil J.L. Osborn K. Iwata Tumour oxygenation is increased by hyperthermia at mild temperatures Int J Hyperthermia 12 1996 367 373
137. B. Rau P. Wust W. Tilly Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters Int J Radiat Oncol Biol Phys 48 2000 381 391
138. G. Calcutt S.M. Ting A.V. Preece Tissue NAD levels and the response to irradiation of cytotoxic drugs Br J Cancer 24 1970 380 388
139. S. Masunaga K. Ono K. Akuta Enhancement of chemosensitivity of quiescent cell populations in murine solid tumors using nicotinamide Chemotherapy 40 1994 418 426
140. D.K. Kelleher P.W. Vaupel Possible mechanisms involved in tumor radiosensitization following nicotinamide administration Radiother Oncol 32 1994 47 53
141. C.E. Peters D.J. Chaplin D.G. Hirst Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner Br J Radiol 70 1997 160 167
142. R.D. Braun J.L. Lanzen S.A. Snyder M.W. Dewhirst Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents Am J Physiol Heart Circ Physiol 280 2001 H2533 H2544
143. J.H. Kaanders J. Bussink A.J. van der Kogel ARCON: a novel biology-based approach in radiotherapy Lancet Oncol 3 2002 728 737
144. K. Warren R. Jakacki B. Widemann Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group Cancer Chemother Pharmacol 58 2006 343 347
145. D.F. Emerich R.L. Dean P. Snodgrass Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors J Pharmacol Exp Ther 296 2001 632 641
146. R. Jirtle K.H. Clifton J.H. Rankin Effects of several vasoactive drugs on the vascular resistance of MT-W9B tumors in W/Fu rats Cancer Res 38 1978 2385 2390
147. D. Fukumura R.K. Jain Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize J Cell Biochem 101 2007 937 949
148. J.H. Kaanders J. Bussink A.J. van der Kogel Clinical studies of hypoxia modification in radiotherapy Semin Radiat Oncol 14 2004 233 240
149. P.L. Olive C. Aquino-Parsons Measurement of tumor hypoxia using single-cell methods Semin Radiat Oncol 14 2004 241 248
150. B.F. Jordan J.P. Galon R.J. Gillies Post-treatment changes in tumor microenvironment: dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging M.A. Hayat Cancer imaging: instrumentation and applications 2008 Academic Press Burlington, USA 235 248